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It has been reported that long non-coding RNA lincRNA-p21 is induced upon radiation and 
chemotherapy. This induction contributes to DNA-damage repair, cell death and cell cycle 
regulation. In this study, we focused on Taxotere (TXT) mediated chemotherapy of breast cancer 
cells and found that lincRNA-p21 is robotically induced upon TXT treatment. Secondly, we 
observed increased chemoresistance in three different breast cancer cell lines with lincRNA-p21 
knockdown. Mechanistically, we found that lincRNA-p21 knockdown lead to decreased cell 
death during chemotherapy comparing to the negative control. In addition, our work showed that 
p21 is a downstream target of lincRNA-p21 in human breast cancer cells, and the loss of 
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More than 1.3 million patients are diagnosed with breast cancer every year all over the 
world. Even with advanced medical care and treatment, about 50,000 people will die from this 
disease each year[1].  Chemoresistance is one of the main reasons for failures in breast cancer 
treatments and tumor recurrence[2].  We now know that cell death deficiency and cell cycle 
dysregulation lead to tumor resistance[3-7]. Various protein-coding gene such as p53 and HER2 
have been reported to influence chemoresponse of breast cancer cells[8, 9]. However, the role of 
long non-coding RNAs (lncRNAs) in regulating breast cancer chemoresistance remains to be 
characterized. More importantly, there is still no accurate prognosis guideline in clinical practice 
to differentiate breast cancer patients who would respond to chemo/radiotherapy from those who 
would not, based on our current knowledge about specific molecular or genetic markers. 
Taxotere (TXT or docetaxel) is a chemotherapeutic drug that has been incorporated into first 
line adjuvant chemotherapy of breast cancer[9, 10].  Mechanistically, TXT promotes the 
assembly and stability of microtubules. As a consequence, TXT blocks cell cycle progression at 
M phase and induces cell death pathway by interrupting microtubules depolymerization[11, 12]. 
As reported before, TXT activates apoptosis pathway by upregulating p21, which is a validated 
downstream target of lincRNA-p21[13, 14].  However, a better understanding on the mechanism 
of TXT action in breast cancer is desired.   
Long non-coding RNA (LncRNA) is a subset of RNA molecule classified based on RNA 
length (longer than 200bp in length) and translational potential (no protein product)[15].  The 
traditional understanding about human genome has focused on protein-coding genes, with the 




technologies have shown that a mere 2% of the human genome was transcribed into mRNA, 
whereas 62.1% of genome was transcribed into non-coding RNAs that were processed.  This 
finding indicates that the non-coding RNAs likely have the potential to affect biological 
functions in human cells[16-18].  For the past decades, lncRNAs were shown to have diverse 
regulatory functions on gene transcriptional process and post-transcriptional regulation, such as 
modulating RNA stability[19-22].  Investigating the biological functions of lncRNAs in 
regulating cell signaling pathways has largely advanced our understanding about multiple 
diseases, including cancer[15]. 
LincRNA-p21 is a ~3kb lncRNA that been identified in 2010 as p53 target and putative 
tumor suppressor[23].  Published data showed that the lincRNA-p21 induction in cells mediated 
by radiation or chemotherapy directly promoted apoptosis, senescence, and the G1/S cell-cycle 
checkpoint[14, 22-28].  Recently, our finding indicates that lincRNA-p21 is also an important 
mediator in taxotere chemotherapy of human breast cancer (Guo et al, manuscript in preparation).  
In brief, we found that TXT treatment rapidly activated lincRNA-p21 expression in human breast 
cancer cells.  And the knockdown of lincRNA-p21 led breast cancer cells to become 
chemoresistant.  At the molecular level, p21 is a downstream target of lincRNA-p21 and the loss 







1. LincRNA-p21 was induced upon chemotherapeutic drug Taxotere treatment in 
human breast cancer 
To validate the suppressive effect of TXT on breast cancer cell growth, we treated human 
breast cancer cell line MDA-MB-231 with two different dosages of TXT and measured the cell 
growth.  After treated for 24 hours, 0.5nM TXT treatment significantly suppressed MDA-MB-
231 cells growth about 58% and 1nM TXT treatment inhibited cell over 90% comparing to 
control. This indicates that growth suppressive effect is dose-dependent (Fig. 1A).   
Previously, published reports showed that the induction of lincRNA-p21 mediated by 
radiation and doxorubicin played an important role in human colon cancer cell stress response.  
However, no evidence showed lincRNA-p21 was involved in TXT-mediated cell chemoresponse.  
To examine if lincRNA-p21 has potential functions in breast cancer TXT chemoresponse, we 
started to quantifying its induction level upon TXT treatment. By performing real-time qPCR, 
we observed that lincRNA-p21 expression level was rapidly upregulated upon TXT treatment 
and final expression level was increased by 15 times.  We also found that the TXT-mediated 
induction of lincRNA-p21 appeared to be dose-dependent (Fig.1C).   
Taken together, our data indicates that chemotherapeutic drug TXT efficiently suppressed the 
growth of human breast cancer cells.  During this process, lincRNA-p21 transcriptional process 
was potently activated.  Based on this observation, we hypothesized that lincRNA-p21 induction 





Fig 1:  LincRNA-p21 was induced upon taxotere (TXT) treatment. 
A. Treating MDA-MB-231 with 0.5nM TXT for 24 hours inhibited cell growth. 
B. LincRNA-p21 was induced by 0.5nM TXT in breast cancer cell line MDA-MB-
231 (0h – 48h). 





2. LincRNA-p21 knockdown promoted breast cancer cell chemoresistance 
To test our hypothesis about the role of lincRNA-p21 in breast cancer cells, we designed and 
synthesized four lincRNA-p21 targeting antisense oligonucleotides (ASOs) for knockdown 
experiment.  Since lincRNA-p21 localized in both the cytoplasm and nucleus[22], ASO/RNaseH 
complex is more efficient in knocking down lincRNA-p21 in both cell compartments comparing 
to RNA-induced silencing complex (RISC) [29, 30].  Before performing functional studies, we 
tested knockdown efficiency of all ASOs in MDA-MB-231 cells and picked the best two ASOs 
(ASO2 and ASO3) for further studies (Fig. 2A).  In addition, we also validated that ASO2 and 
ASO3 efficiently blocked lincRNA-p21 in the presence of TXT (Fig. 2B). 
To better understand its roles in breast cancer cells, we performed lincRNA-p21 knockdown 
assay in three different breast cancer cell lines: MDA-MB-231, BT-483 and HS-578T.  We chose 
these three cell lines for two reasons: 1) lincRNA-p21 was expressed (data not shown); 2) they 
include ER+ (BT-483) and ER- (MDA-MB-231, HS-578T) breast cancer cells [31].  We used 
MTT-based cytotoxicity assay to evaluate cell chemoresistant level.  IC-50 represented half-
maximal inhibitory concentration.  High IC-50 indicated high resistant level of the cell to the 
compound.  With lincRNA-p21 knocked down, the IC-50 of MDA-MB-231 upon TXT treatment 
was almost doubled comparing to negative control (NC) group. This indicates that lincRNA-p21 
promotes TXT resistance (Fig. 2C).  This phenotype was also observed in two other breast 
cancer cell lines, BT-483 (ER+) and HS-578T (ER-) (Fig. 2C).  However, the effect of lincRNA-
p21 knockdown on chemoresistance was less significant in HS-578T and BT-483 cells.  We 
deduced it could likely be attributed to the low transfection efficiency and high resistance to 




Based on previous studies, lincRNA-p21 is a p53 target and its function is highly dependent 
on p53[23, 26, 28, 32]. Our finding showed that lincRNA-p21 also has function in p53-null (BT-
483) and p53-mutant (HS-578T, MDA-MB-231) breast cancer cells.  This demonstrates that the 
regulatory network of lincRNA-p21 in breast cancer potentially has p53-dependent and p53-
independent mechanisms for gene expression.   In conclusion, we found that TXT suppressed 





     
Fig 2:  LincRNA-p21 knockdown promoted breast cancer cell chemoresistance. 
A. Diagram of lincRNA-p21 ASO locus and the efficiency of knockdown in MDA-MB-
231 cells. 
B. ASO blocks lincRNA-p21 induction mediated by 1nM TXT in MDA-MB-231 cells. 
C. LincRNA-p21 knockdown increases breast cancer cell chemoresistance of MDA-MB-




3. LincRNA-p21 knockdown increased cell growth while blocking cell death 
To date, no study has examined lincRNA-p21’s function in breast cancer. By knocking down 
lincRNA-p21 in three breast cancer cell lines (MDA-MB-231, BT-483 and HS-578T), we 
observed a consistent phenotype in all three cell lines that lincRNA-p21 knockdown significantly 
promoted cell growth as compared to negative control (Fig.3A).  To quantify the influence of 
lincRNA-p21 knockdown on cell growth, we performed Acridine Orange and Propidium Iodide 
(AO/PI) staining assay with or without TXT treatment on MDA-MB-231 cells (Fig. 3B).  As 
shown in Figure 3B, knockdown groups had significantly higher numbers of living cells than that 
of negative control for both conditions.  This data confirm the potential tumor suppressive role of 
lincRNA-p21 in breast cancer cells. The lincRNA-p21 knockdown efficiency was lower in HS-
578T and BT-483 cells (Fig. 3E, 3F), which might explain why lincRNA-p21 knockdown was 
less potent in altering chemoresistance and cell growth in these two cell lines.   
 Furthermore, AO/PI staining results also showed that lincRNA-p21 knockdown increased 
breast cancer cell survival (Fig. 3G, 3H).  More relevant to chemoresistance, we tested this effect 
of lincRNA-p21 knockdown upon TXT treatment.  Consistent with above data, the loss of 
lincRNA-p21 directly led to robotic cell growth increase with decreased cell death after TXT 










Fig 3:  LincRNA-p21 knockdown promoted cell growth while blocking cell death. 
A. Cells with lincRNA-p21 knocked down grew faster than NC (MDA-MB-231, BT-
483, HS-578T).  
B. Living MDA-MB-231 cell number with (lower) or without (upper) TXT treatment 
tested by AO/PI staining. 
C. Percentage of dead MDA-MB-231 cells with (lower) or without (upper) TXT 
treatment.  




4. p21 is a downstream target of lincRNA-p21  
To identify downstream targets of lincRNA-p21 in breast cancer, we performed qPCR and 
Western blot with lincRNA-p21 knockdown samples.  Previously, p21 was demonstrated to be 
the direct target of lincRNA-p21.  Specifically, lincRNA-p21 activated P21 transcription in cis 
by recruiting hnRNPK and transcriptional activators to its promoter[14].  p21 acts as cell cycle 
and cell death regulator[3].  We hypothesize that lincRNA-p21 regulates breast cancer cell cycle 
distribution and cell death by activating p21.  Our data showed that lincRNA-p21 knockdown led 
to decrease in p21 expression at both RNA and protein levels in MDA-MB-231 cells (Fig. 4A 
left, 4B).  This regulatory relationship was also confirmed upon TXT treatment (Fig. 4A right). 
Currently, we are working on optimizing the PI staining flow-cytometry protocol to validate this 
hypothesis.  Besides P21 gene, the expression of BRCA1 was also downregulated while 
knocking down lincRNA-p21 in breast cancer cells.  Based on literature, BRCA1/p21 pathway is 
involved in cell cycle arrest upon stresses such as chemotherapy[5, 33, 34].  It is reasonable to 
deduce that lincRNA-p21 enhances breast cancer chemoresponse through activating BRCA1/p21 














Fig 4:  p21 is downstream target of lincRNA-p21 in breast cancer. 
A. Real-time qPCR quantification of P21 in MDA-MB-231 cells with (right) or 
without (left) taxotere treatment. 
B. Western Blot of p21 protein in MDA-MB-231 cells. 




5. dCas9-CRISPR mediated lincRNA-p21 activation 
      When we started this project, only a partial sequence of human lincRNA-p21 had been 
published and the remaining sequence was unknown[22].  Hence, all human lincRNA-p21 
overexpression experiments used partial human lincRNA-p21 expressing vector[22, 26, 27, 35].  
Since long non-coding RNAs function as RNA molecules instead of protein molecules, using a 
partial RNA sequence likely alters lncRNA functional domains and its activities.  To better 
understand the functions and downstream targets of lincRNA-p21, we applied dCas9-CRISPR 
mediated gene activation (CRISPRa) system to achieve endogenous human lincRNA-p21 
‘overexpression’[36].   
CRISPR technology is a new and efficient gene editing method recently established(ref). 
Mechanistically, Cas9 nuclease is guided by specific 20 base single guide RNA (sgRNA) to the 
targeting genome locus through nucleic acid base-paring and achieves gene editing [37, 38].  
After being established in 2012, CRISPR technology is widely used in numerous areas.  
Different from traditional Cas9-CRISPR, CRISPRa uses the catalytically inactivated dCas9-
sgRNA complex to target gene promoter and activate gene transcriptional process [39].  In brief, 
dCas9 protein is fused to the transcriptional activator, VP64. The modified sgRNA bears MS2 
stemloops, which brings two extra activators (P65, HSF1) through MS2 aptamer-mediated 
recruitment.  During activation process, sgRNA-P65-HSF1 complex associates with dCas9-
VP64 fusion protein and then binds to its targeting gene promoter.  This system induces 
endogenous gene expression in cells that captures the complexity of transcript isoform variance.  
        Based on literature, sgRNAs that target the first 200bp upstream from transcriptional start 
site (TSS) have the best activation efficiency[36].  Since we only had a partial lincRNA-p21 




in human genome.  We reached the epigenetic signatures of human lincRNA-p21 using 
sequencing data from Roadmap Epigenomic Project [40, 41].  H3K27ac and H3K4me1 are two 
markers that frequently appear at promoter region [42].  The promoter region is also marked with 
enriched DNaseI hypersensitive sites and transcriptional factor binding sites.  As a consequence, 
the sequencing data indicated that the 1000bp upstream of the partial lincRNA-p21 sequence 
likely contains the promoter region and the +1 site TSS (Fig. 5A).  Recently, the full-length 
sequence of human lincRNA-p21 has been published [43].  Our prediction is consistent with this 
new finding.   
      With this information, we designed four sgRNAs for CRISPRa assay using online tools (Fig. 
5B).  Considering the low transfection efficiency of breast cancer cells, we initially tested the 
CRISPRa system in HEK-293FT cells.  As shown in Fig. 5C, sgRNA1/2/3 all activated 
lincRNA-p21 expression with different efficiencies.  This result was consistent with original 
publication [36], that the closer the sgRNA is to TSS, the more efficient activation it achieves.   
To make sure the activation was mediated by CRISPRa system and not by non-specific 
effects, we designed and developed lincRNA-p21 promoter luciferase assay (Fig. 5D upper).  
The luciferase assay was conducted in HEK-293FT cells for 24 h ours and 48 hours after 
transfection.  As shown in Figure 5D (lower panel), comparing to two negative controls, four 
lincRNA-p21 sgRNAs significantly activated the transcriptional process from lincRNA-p21 
promoter.   
To improve the activation efficiency, we established the HEK-293FT dCas9-complex 
lentiviral stable cell line and performed CRISPRa using this cell line.  Consistent with our 




CRISPRa. To examine tissue specificity, the activation assay will be tested on breast cancer cells 
in the future studies.   








       
  
Fig 5: LincRNA-P21 CRISPR activation system. 
A. Epigenetic modification and lincRNA-p21 promoter prediction.  
B. Designing of lincRNA-p21 CRISPR activation system. 
C. CRISPRa efficiency in HEK-293ft lenti-dCas9 cells. 
D. Validation of CRISPRa specificity in HEK-293ft cells: luciferase assay. 





Breast cancer is one of the most common solid tumors, which affect about 12% women in 
US.  Failure to respond to chemotherapy represents a critical problem in breast cancer 
treatment[44]. After decades of exploration, the mechanism of chemoresistance still remains not 
totally clear.  Incorporating a new component promoting chemosensitivity into current cancer 
chemotherapy would provide immense clinical relevance that would benefit cancer patients.  
Long non-coding RNAs (lncRNAs) have emerged as important regulators of many cellular 
processes including chemoresponse.  Among lncRNAs, lincRNA-p21 has been shown as a 
crucial tumor suppressor in many cancer types[14, 23, 26-28, 45]. However, the significance of 
lincRNA-p21 in breast cancer chemoresistance remains to be characterized.   
Our results indicate that lincRNA-p21 is a phenotypic regulator of breast cancer 
chemosensitivity upon TXT treatment.  LincRNA-p21 is highly upregulated during 
chemotherapy and suppress tumor growth.  To our knowledge, this is the first study examining 
the role of lincRNA-p21 in human breast cancer and TXT chemotherapy.  Taxotere is a first line 
chemotherapeutic drug that has been used in breast cancer treatment for decades.  The p21 
pathway contributes to TXT-mediated tumor suppression.  Our finding provided a new layer of 
understanding of p21 regulation in TXT treatment and chemoresistance.   
By now, we only used lincRNA-p21 knockdown to exam the role of lincRNA-p21 in breast 
cancer.  For the future study, experiments on validating lincRNA-p21 functions and downstream 
targets are needed to have a better understand the mechanism of action.  Specifically, it will be 
valuable to test and optimize our CRISPR activation system which achieves endogenous human 
lincRNA-p21 ‘overexpression’ on breast cancer cells.  First, though the human lincRNA-p21 




endogenous activation and covering all transcript isoforms.  Secondly, our current lincRNA-p21 
CRIPSR activation system hasn’t achieve significant effect on any breast cancer cells.  This 
could possibly due to: 1) low transfection efficiency; 2) histone modification on sgRNA binding 
sites.  To solve this potential problem, we will establish lenti-viral CRISPRa system and test 
more sgRNAs.  As double validation, we will overexpress human lincRNA-p21 using expression 
plasmid and compare the phenotype with the one of CRISPRa to conclude lincRNA-p21 
functions in breast cancer. 
In addition, extra experiments such as rescue study can be conducted to validate p21 as the 
direct target of lincRNA-p21 upon TXT treatment.  With the activation and overexpression tools 
available, we will be able to perform additional functional studies with human lincRNA-p21.  In 
addition, our data show that BRCA1 mRNA abundance was altered in lincRNA-p21 knockdown 
samples.  This demonstrates that BRCA1 might be a novel and relevant target of lincRNA-p21 in 
human breast cancer.  Based on literature, BRCA1 regulates p21 expression, which is highly 
involved in breast cancer chemoresponse. Further studies related to the regulatory relationship 
between lincRNA-p21 and BRCA1 could be conducted in the future. 
Lastly but not the least, we found that tumor suppressor lincRNA-p21 was not significantly 
lost from breast cancer cells comparing to normal cells.  LincRNA-p21 is a highly dynamic 
lncRNA whose half-life is less than 2 hours.  We hypothesized that the induction of lincRNA-
p21 upon taxotere treatment was correlated with breast cancer chemosensitivity.  As a 
consequence, further assays of determining the expression of lincRNA-p21 in taxotere-treated 
breast cancer cells and correlating lincRNA-p21 response with the cells’ chemosensitivity should 
be performed.  These findings will contribute to identifying new biomarkers and incorporating 




Materials and Methods 
Cell Culture, Transfection and Antisense Oligonucleotide 
Human breast cancer cell lines MDA-MB-231, BT-483 and HS-578T were cultured in DMEM 
(Invitrogen) supplemented with 10% FBS and antibiotics in a 37° and 5% CO2 –humidified incubator. All 
Antisense Oligonucleotides (2’OMe-ASOs) including NC ASO were purchased from IDT (Integrated 
DNA Technologies) diluted with RNase/DNase free water into 20mM. ASOs are listed in Table1.  Cells 
(300,000 cells/well MDA-MB-231, 100,000 cells/well HS-578T, 300,000 cells/well BT-483 were seeded 
into 6-well-plate 24 hours before transfection.  Cells were transfected with ASO at 20nM (MDA-MB-231, 
BT-483) or 30nM (HS-578T) final concentration using lipofectamine 2000 (Invitrogen).  Culture media 
was changed 5 hours after transfection.   
Western Blot Analysis 
After 48 hours of transfection with ASOs, cells were washed twice with cold PBS and collected.  Whole-
cell lysates prepared in RIPA buffer were separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE), and transferred onto PVDF membranes. Primary antibodies were used: anti-P21 (Cell Signaling) 
and anti-tubulin (Sigma). 
CRISPR activation 
CRISPR activation was performed as previously described [36].  sgRNA sequence were listed in Table2. 
All plasmids used were obtained from Addgene.  In brief, lenti-dCas9 HEK293ft cells were maintained in 
high-glucose DMEM with GlutaMAX.  450,000cells/well lenti-dCas9 HEK293ft were plated in 6-well-
plate 24 hours before transfection.   For lincRNA-p21 activation, 1µg sgRNA plasmid were transfected 
using lipofectmine2000 (1:2.5 ratio).  Media were changed 5h post-transfection.  
Promoter Luciferase Reporter Assay 
The promoter region of lincRNA-p21 (1kb) was cloned into pGL4.20 [luc/Puro] vector (Promega). 




pGL4-lincp21 and Renilla. 48h or 72h after transfection, cells were harvested and assayed using the Dual-
Luciferase Reporter Assay System (Promega).  
AOPI staining 
AOPI staining was performed using VisStain
TM
 AOPI Staining Solution in PBS and Cellometer from 
Nexcelom following manufacturer’s instructions. 
MTT-based Cytotoxicity Assay 
5,000 cells/well were plated in 96-well-plate and treated with serially diluted TXT in triplicates.  After 4 
to 6 days, WST-8 (Sigma) and plate reader were used to measure the result as described previously [46].   
RNA extraction, cDNA synthesis and real-time PCR analysis.  
Total RNA was extracted using Direct-zol® MiniPrep kit (Zymo Research) following manufacturer’s 
instructions. The cDNA synthesis was performed using random primer and SuperScript
TM 
III Reverse 
Transcriptase (Invitrogen).  Quantitative real-time PCR was performed using gene specific primers (listed 
in Table3), SYBR® Selected Master Mix (Applied Biosystems, Life Technologies) and normalized to 
GAPDH.    








NC ASO mG*mC*mG*mA*mC*T*A*T*A*C*G*C*G*C*A*mA*mU*mA*mU*mG 
 
Table 2. LincRNA-p21 CRISPRa sgRNAs 
sgRNA Sequence Cite 
sgRNA1 TGCTGATGCGAGGCGATGCACGG  
sgRNA2 AAGCTCATGGCTGAGTGAGCAGG  
sgRNA3 TCAACGGACCCTTTAACCCCTGG  
sgRNA4 GTGGGGAGCTTTCAATTACCTGG  
NC sgRNA1 GTGGGGAGCTTTCAATTACCTGG [36] 





Table 3. Primers 
 Human lincRNA-p21 promoter clone primers: 
  
Real-time PCR primers: 
Primer Sequence Cite 
lincRNA-p21-F79 GGGTGGCTCACTCTTCTGGC [22] 
lincRNA-p21-R19 TGGCCTTGCCCGGGCTTGTC [22] 
GAPDH-F490 (Hu) ATGTTCGTCATGGGTGTGAA  
GAPDH-R578 (Hu) GGTGCTAAGCAGTTGGTGGT  
P21-F GGCGGCAGACCAGCATGACAGATT  
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